Evidence map›Paper›PMID 35082997›Full record

ArticleInternational journal of hematology-oncology and stem cell research2021

p53 p.Pro72Arg (rs1042522) and Mouse Double Minute 2 (MDM2) Single-Nucleotide Polymorphism (SNP) 309 Variants and Their Interaction in Chronic Lymphocytic Leukemia(CLL): A Survey in CLL Patients from Western Iran.

Nazanin Jalilian, Yosra Maleki, Ebrahim Shakiba, Mozafar Aznab, Ziba Rahimi, Mehdi Salimi, Zohreh Rhimi

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology-oncology and stem cell research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Comprehensive Meta-Analysis on the Impact of theCurrent pharmaceutical design · 2026
    Pooled it
  2. Article
  3. Frontiers in oncology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Nazanin JalilianDepartment of Clinical Biochemistry, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Yosra MalekiDepartment of Clinical Biochemistry, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Ebrahim ShakibaDepartment of Clinical Biochemistry, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mozafar AznabDepartment of Internal Medicine, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Ziba RahimiMedical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mehdi SalimiDepartment of Internal Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Zohreh RhimiDepartment of Clinical Biochemistry, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Kermanshah University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Chronic lymphocytic leukemia (CLL)Gene-gene interactionGene polymorphismMouse double minute 2 (MDM2)p53 gene

Identifiers

PMID35082997
PMCPMC8748241
OpenAlexW3192184926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.